Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Filings indexed 1,245 across all filing types
Latest filing 2023-05-11 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Dividend Updates
Regulatory Filings
2023-05-11 English
We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 11, 2023 at the registered office of the Company. In pursuant to Regulation ....
Regulatory Filings
2023-05-11 English
Financial Result Updates
Regulatory Filings
2023-05-11 English
Board Meeting — BLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 11-May-2023 to consider financial statements for the period ended March 2023, Financial results/Di…
Regulatory Filings
2023-05-05 English
Board Meeting Intimation
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them of an upcoming Board Meeting scheduled for May 11, 2023. The agenda includes consideration and approval of audited financial results for the quarter and year ended March 31, 2023, and discussion of a final dividend. The document does not contain the financial results themselves but rather an announcement of the meeting where these results will be approved. The document length is short (2445 characters), and it states that the results will be considered and approved at the meeting, indicating this is a notice rather than the report itself. Therefore, this fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification of a board meeting, not the actual financial report or earnings release.
2023-05-04 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2023 ,inter alia, to consider and approve a) To consider and approve ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them of an upcoming Board Meeting scheduled for May 11, 2023. The agenda includes consideration and approval of audited financial results for the quarter and year ended March 31, 2023, approval of audited financial statements for the financial year ended March 31, 2023, and discussion of a final dividend. The document is an announcement of a future event (Board Meeting) and does not contain actual financial data or the financial results themselves. The document length is short (2445 characters), and it serves as an intimation or notice rather than a full report. Therefore, it is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Audit Report (AR). It is also not a Board/Management Information (MANG) announcement about changes in board or management. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement informing the stock exchanges and public about the scheduled Board Meeting and its agenda, which includes approval of financial results and dividend declaration.
2023-05-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.